肝苏颗粒联合恩替卡韦对慢性乙型肝炎患者肝纤维化及乙型肝炎病毒-DNA转阴率的影响

摘要

Objective To explore the effect of Gansu granule combined with entecavir on liver fibiosis and the negative conversion rate of hepatitis b virus-DNA( HBV-DNA) in patients with chronic hepatitis B. Methods Four hundred and twenty patients with chronic hepatitis B were divided into two groups, two hundred and ten cases in each group. The patients in control group were treated with entecavir,and the patients in observation group were treated with enleeavir and Gansu granula. The recovery rate of liver function and the changes of hepatic fibrosis and HBV-DNA were observed and compared. Results In two groups, the recovery rate of liver function in the treatment of one year was significantly higher than that in the treatment of three months( P <0.05). The recovery rate of liver function in observation group was higher than that in control group in the treatment of three months,six months and one year( P <0.05). There was no statistical difference in hepatic fibrosis between two groups before treatment(P >0.05). One year treatment later,the values of hepatic fibrosis index were significantly lower than those before treatment(P <0.05) ,but the improvement of hepatic fibrosis in observation group was more than that in control group(P<0. 05). With the extension of treatment time, the negative conversion rale of HBV-DNA gradually increased(P < 0. 05). In the treatment of three months,six months and one year,there was no statistical difference in the negative conversion rate of HBV-DNA between two groups( P >0.05). Conclusion Gansu granule combined with enlecavir can significantly improve liver function and hepatic fibrosis in patients with chronic hepatitis B, but has no effect on the negative conversion of HBV-DNA.%目的 探讨肝苏颗粒联合恩替卡韦对慢性乙型肝炎患者肝纤维化及乙型肝炎病毒(HBV)-DNA转阴率的影响.方法 420例慢性乙型肝炎患者分为2组,每组210例.对照组给予恩替卡韦治疗,观察组给予恩替卡韦联合肝苏颗粒治疗,观察比较2组患者的肝功能复常率、肝纤维化及HBV-DNA的变化.结果 2组患者治疗1 a时肝功能复常率均显著高于治疗3个月时(P＜0.05),观察组在治疗3、6个月及1 a时肝功能复常率高于对照组(P＜0.05).2组治疗前肝纤维化程度比较差异无统计学意义(P＞0.05)；2组治疗1 a时肝纤维化指标显著低于治疗前(P＜0.05),观察组肝纤维化改善显著优于对照组(P＜0.05).随着治疗时间的延长,2组患者HBV-DNA转阴率逐渐升高(P＜0.05)；2组患者在治疗3、6个月及1 a时HBV-DNA转阴率比较差异均无统计学意义(P＞0.05).结论 肝苏颗粒联合恩替卡韦可显著改善慢性乙型肝炎患者肝功能及肝纤维化,但对HBV-DNA转阴无明显影响.